Artesunate
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
eluxadoline
MOR agonist; DOR antagonist; KOR agonist · Gastrointestinal motility agent
MOR agonist; DOR antagonist; KOR agonistGastrointestinal motility agentATC A07DA05
CDSCO approvedATC A07DA05
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- ArtesunateSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
- BexaroteneSevereDatabaseDDInter
- CobicistatSevereDatabaseDDInter
Mechanism
Eluxadoline is a mixed mu opioid receptor (MOR) agonist, delta opioid receptor (DOR) antagonist, and kappa opioid receptor (KOR) agonist. It acts locally in the GI tract to reduce abdominal pain and diarrhea without causing significant constipation.
Indications
Diarrhea-predominant IBS (in adults)
Dosing
- Adult
- 100 mg twice daily with food (for diarrhea-predominant IBS with a gallbladder). 75 mg twice daily (for patients without a gallbladder).
Pharmacokinetics
Peak effect
1.5 to 2 h
Half-life
3.7 to 6 h
Excretion
In feces (drug and metabolic products)
Contraindications
- Known or suspected biliary duct obstruction
- Sphincter of Oddi disease or dysfunction
- History of pancreatitis
- Structural diseases of the pancreas
- Patients without a gallbladder (dosing adjustment required)
Side effects
Common
ConstipationNauseaAbdominal pain
Serious
- Sphincter of Oddi spasm
- Pancreatitis
- Potential for addiction
Drug interactions
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Bexarotene
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cobicistat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Cyclosporine
Severe
Database
Clinical effect not specified
Source: DDInter
Daclatasvir
Severe
Database
Clinical effect not specified
Source: DDInter
Darolutamide
Severe
Database
Clinical effect not specified
Source: DDInter
Eltrombopag
Severe
Database
Clinical effect not specified
Source: DDInter
Ethanol
Severe
Database
Clinical effect not specified
Source: DDInter
Gemfibrozil
Severe
Database
Clinical effect not specified
Source: DDInter
Grazoprevir
Severe
Database
Clinical effect not specified
Source: DDInter
Lapatinib
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about eluxadoline
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team